Evommune Slumps 45% After Phase 2 Flop for Eczema Drug EVO756
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
evommuneclinical-trial
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Evommune Therapeutics shares collapsed on June 29, 2026, following the release of disappointing Phase 2 clinical trial data for its lead candidate, EVO756, in chronic spontaneous urticaria. The stock fell 45% in pre-market trading, erasing approximately $550 million in market capitalization. The data, announced by the company, showed EVO756 failed to achieve statistical significance on its primary efficacy endpoint compared to placebo, a major setback for the clinical-stage biotech.
The failure of EVO756 is a significant event in the immunology and dermatology treatment landscape. Chronic spontaneous urticaria and atopic dermatitis represent multi-billion dollar market opportunities, with blockbuster drugs like Dupixent from Sanofi and Regeneron dominating the space. The last major Phase 2 failure in this category was Galderma's nemolizumab in 2024, which saw a 30% stock decline on similar efficacy concerns.
The current macroeconomic backdrop of higher interest rates has increased scrutiny on cash-burning biotech firms, making positive clinical data essential for sustaining valuations. Evommune was banking on a strong EVO756 readout to secure additional funding or attract partnership interest. The trial's failure directly impacts the company's ability to advance its pipeline and maintain its current valuation multiple, triggering a repricing of risk.
The Phase 2 trial evaluated EVO756 in 240 patients with moderate-to-severe chronic spontaneous urticaria. The primary endpoint was the change from baseline in the Urticaria Activity Score (UAS7) at week 12. EVO756 demonstrated only a 12.5-point reduction in UAS7, compared to a 10.1-point reduction for the placebo group. This 2.4-point difference failed to meet the pre-specified threshold for statistical significance (p=0.23).
Secondary endpoints, including the proportion of patients achieving well-controlled disease, also showed no significant improvement. The drug's safety profile was comparable to placebo, with no new safety signals identified. Evommune's cash position was reported at $180 million as of its last quarterly filing, which management previously stated was sufficient to fund operations into late 2027. The company's market cap now stands near $670 million, down from over $1.2 billion prior to the data release. Peer company Arcutis Biotherapeutics, focused on dermatology, trades at a market cap of $2.1 billion.
| Metric | EVO756 Group | Placebo Group |
|---|---|---|
| UAS7 Reduction (Week 12) | -12.5 points | -10.1 points |
| Statistical Significance | p=0.23 | N/A |
The clinical failure immediately impacts Evommune's competitive positioning. The company's pipeline is now heavily de-risked, shifting investor focus to earlier-stage assets without a near-term catalyst. This data miss may benefit established players like Sanofi [SNY] and Regeneron [REGN], whose lead drug Dupixent faces one less potential long-term competitor in the immunology space. Smaller, clinical-stage dermatology firms like Arcutis Biotherapeutics [ARQT] and Cara Therapeutics [CARA] could see increased investor interest as alternatives for exposure to the market.
A counter-argument is that Evommune's other oral PDE4 inhibitor programs for atopic dermatitis may still hold value, though investor confidence in the platform is likely severely damaged. Trading flow data indicates heavy selling from institutional holders, with short interest having climbed to 8% of the float in the weeks leading to the data readout. Options activity suggests traders are positioning for further downside, with elevated put volume at strikes 30% below the current price.
The immediate catalyst for Evommune is its scheduled investor conference call to discuss the data, expected later today. Management's commentary on the future of the EVO756 program and the broader pipeline will be critical. The next major clinical milestone is the Phase 2b readout for EVO800 in atopic dermatitis, expected in Q1 2027.
Key levels to watch for the stock are the $5.00 psychological support level, a further 25% decline from current prices. A break below this could signal a re-rate toward the value of the company's cash on hand. Investors should monitor for any partnership announcements or strategic reviews that could provide a floor for the valuation. The XBI Biotech ETF is also a key indicator for broader sector sentiment toward high-risk clinical assets.
The failure of EVO756 reduces near-term competitive pressure on established biologic drugs for inflammatory skin conditions. Market leaders like Sanofi and Regeneron's Dupixent, which generated $12.2 billion in 2025 sales, benefit from one less potential entrant in the oral treatment segment. It also highlights the high bar for efficacy in urticaria trials, potentially increasing the perceived value of drugs with proven late-stage data. The setback may make investors more cautious about other oral PDE4 inhibitors in development.
Evommune's 45% drop is severe but within the range for a lead-asset Phase 2 failure. In 2024, Galderma shares fell 30% after nemolizumab missed endpoints. A more extreme example was Zymeworks' 65% crash in 2023 after its cancer therapy data disappointed. The magnitude of Evommune's decline reflects EVO756's status as the company's most advanced program and the primary driver of its valuation. The high short interest preceding the data amplified the downward move.
Historical success rates from Phase 2 to Phase 3 approval in dermatology are approximately 30%, according to industry benchmarks. This is slightly below the overall biopharma average of 33%. The high failure rate underscores the significant risk inherent in clinical-stage biotech investing. For urticaria specifically, the pathway has been challenging, with several late-stage programs from larger pharmaceutical companies also failing to demonstrate sufficient efficacy over placebo in recent years.
Evommune's valuation reset reflects the binary nature of clinical-stage biotech investing.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.